Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

M. Holanek, I. Selingerova, P. Fabian, O. Coufal, O. Zapletal, K. Petrakova, T. Kazda, R. Hrstka, A. Poprach, M. Zvarikova, O. Bilek, M. Svoboda

. 2022 ; 12 (7) : . [pub] 20220718

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22023695

Grant support
MMCI 00209805 Ministry of Health
NU22-08-00230 Ministry of Health
LX22NPO5102 Ministry of Education Youth and Sports
LM2018128 Ministry of Education Youth and Sports
LM2018125 Ministry of Education Youth and Sports

A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecutive patients, including 468 patients with assessable residual cancer burden (aRCB) after NAT, with a median follow-up of 36 months, evaluated the biomarkers assessed before NAT from a biopsy and after NAT from a surgical specimen, their dynamics, and effect on long-term outcomes in specific breast cancer subtypes. The leading focus was on proliferation index Ki-67, which was significantly altered by NAT in all BC subtypes (p < 0.001 for HER2 positive and luminal A/B HER2 negative and p = 0.001 for TNBC). Multivariable analysis showed pre-NAT and post-NAT Ki-67 as independent predictors of survival outcomes for luminal A/B HER2 negative subtype. For TNBC, post-NAT Ki-67 was significant alone, and, for HER2 positive, the only borderline association of pre-NAT Ki-67 was observed in relation to the overall survival. Steroid and HER2 receptors were re-assessed just in a portion of the patients with aRCB. The concordance of both assessments was 92.9% for ER status, 80.1% for PR, and 92.2% for HER2. In conclusion, these real-world data of a consecutive cohort confirmed the importance of biomarkers assessment in patients with aRCB, and the need to consider specific BC subtypes when interpreting their influence on prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023695
003      
CZ-PrNML
005      
20221031095100.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/diagnostics12071740 $2 doi
035    __
$a (PubMed)35885644
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Holanek, Milos $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic $1 0000000312261593
245    10
$a Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy / $c M. Holanek, I. Selingerova, P. Fabian, O. Coufal, O. Zapletal, K. Petrakova, T. Kazda, R. Hrstka, A. Poprach, M. Zvarikova, O. Bilek, M. Svoboda
520    9_
$a A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecutive patients, including 468 patients with assessable residual cancer burden (aRCB) after NAT, with a median follow-up of 36 months, evaluated the biomarkers assessed before NAT from a biopsy and after NAT from a surgical specimen, their dynamics, and effect on long-term outcomes in specific breast cancer subtypes. The leading focus was on proliferation index Ki-67, which was significantly altered by NAT in all BC subtypes (p &lt; 0.001 for HER2 positive and luminal A/B HER2 negative and p = 0.001 for TNBC). Multivariable analysis showed pre-NAT and post-NAT Ki-67 as independent predictors of survival outcomes for luminal A/B HER2 negative subtype. For TNBC, post-NAT Ki-67 was significant alone, and, for HER2 positive, the only borderline association of pre-NAT Ki-67 was observed in relation to the overall survival. Steroid and HER2 receptors were re-assessed just in a portion of the patients with aRCB. The concordance of both assessments was 92.9% for ER status, 80.1% for PR, and 92.2% for HER2. In conclusion, these real-world data of a consecutive cohort confirmed the importance of biomarkers assessment in patients with aRCB, and the need to consider specific BC subtypes when interpreting their influence on prognosis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Selingerova, Iveta $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic $1 0000000337133504
700    1_
$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Coufal, Oldrich $u Department of Breast, Skin and Oncoplastic Surgery, Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Zapletal, Ondrej $u Department of Breast, Skin and Oncoplastic Surgery, Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Petrakova, Katarina $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic $1 0000000172888975
700    1_
$a Hrstka, Roman $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $1 0000000261392664
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Zvarikova, Maria $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Bilek, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
773    0_
$w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 12, č. 7 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35885644 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095058 $b ABA008
999    __
$a ind $b bmc $g 1853978 $s 1174983
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 7 $e 20220718 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
GRA    __
$a MMCI 00209805 $p Ministry of Health
GRA    __
$a NU22-08-00230 $p Ministry of Health
GRA    __
$a LX22NPO5102 $p Ministry of Education Youth and Sports
GRA    __
$a LM2018128 $p Ministry of Education Youth and Sports
GRA    __
$a LM2018125 $p Ministry of Education Youth and Sports
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Archiving options